Clinical trials: Malignant Solid Tumours
Malignant Melanoma, Lung Cancer, or Colorectal Cancer
A Clinical Trial of TAA06 Injection in Advanced Solid Tumors
B7-H3 (also known as CD276) is widely expressed on the surface of a variety of malignancies solid tumors, while it rarely or even doesn't express on normal tissues.
- Trial name
- NCT05190185
- Testing
- TAA06 injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Malignant Neoplasmas, Solid Tumors
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Treatment of cancer is often more effective when two or more drugs are used together. For example, when gemcitabine, an approved drug, and ON 01910.Na, a new investigational anti-cancer drug, are used together to treat cancer…
- Trial name
- NCT01125891
- Testing
- gemcitabine, ON 01910.Na
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Traws Pharma, Inc.
Solid Tumor
HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
A phase Ib, dose escalation, multiple dose trial with HuMax-IL8 in patients with metastatic or unresectable, locally advanced malignant solid tumors.
- Trial name
- NCT02536469
- Testing
- HuMax-IL8
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Thoracic Solid Malignant Tumor
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
To evaluate the safety and efficacy of Boron Neutron Capture Therapy (BNCT) in patients with recurrent thoracic solid tumors that are difficult to treat with standard radiation therapy or drug therapy and are unresectable.
- Trial name
- NCT06603987
- Testing
- BNCT, ［18F］FBPA
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Stella Pharma Corporation
Effect of Drug
Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.
Dose escalation of ORIN1001 in patients with advanced solid tumors. Dose escalation of ORIN1001 in combination with standard of care in patients with esophageal carcinoma, metastatic breast cancer, hepatocellular carcinoma…
- Trial name
- NCT05154201
- Testing
- ORIN1001
- Where
- 13 sites in China
- Volunteers
- 150 people
- Sponsor
- Orinove, Inc.
Advanced Malignant Solid Tumor
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer.
- Trial name
- NCT06150183
- Testing
- BNT314
- Where
- 14 sites in United States, Belgium and 4 more
- Volunteers
- 41 people
- Sponsor
- BioNTech SE
Leptomeningeal Metastasis, Solid Tumor, Adult
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
Adults with leptomeningeal metastasis from solid tumors will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.
- Trial name
- NCT04315246
- Testing
- radiolabeled DPTA-omburtamab
- Where
- 8 sites in United States, United Kingdom
- Sponsor
- Y-mAbs Therapeutics
Malignant Solid Tumors, Lymphoma
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.
- Conditions
- Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03205176
- Testing
- AZD5153, Olaparib
- Where
- 4 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Advanced Malignant Solid Tumors
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-295S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor.
- Trial name
- NCT04908046
- Testing
- HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Hutchmed
Advanced Malignant Solid Tumor
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety, tolerability and preliminary efficacy of 9MW3811 in patients with advanced solid tumors.
- Trial name
- NCT05911984
- Testing
- 9MW3811 Injection
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
EBV-induced Lymphomas, EBV-associated Malignancies
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
- Trial name
- NCT00002663
- Testing
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Atara Biotherapeutics
Malignant Neoplasms
Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors
Phase I study of YKYY031 for injection in patients with advanced solid tumors
- Trial name
- YKYY031，tumors (NCT07631793)
- Testing
- YKYY031 group (the first stage), YKYY031 group (the second stage)
- Where
- 2 sites in China
- Volunteers
- 76 people
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Recurrent or Metastatic Solid Tumors
An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
- Trial name
- A-337 (NCT06093698)
- Testing
- Recombinant Anti-EpCAM-CD3 Antibody Injection
- Volunteers
- 94 people
- Sponsor
- ITabMed Co., Ltd.
Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid…
- Conditions
- Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas
- Trial name
- NCT07713732
- Testing
- TLN-499, Venetoclax
- Where
- 3 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Treeline Biosciences, Inc.
Neoplasms
Study Evaluating CMD-193 in Advanced Malignant Solid Tumors
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of CMD-193. Preliminary information about how a person's body processes CMD-193 and how CMD-193 affects tumors will also be collected.
- Trial name
- NCT00161642
- Testing
- CMD-193
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Malignant Solid Tumor, Lymphomas
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies.
- Trial name
- DINAMIC (NCT01359982)
- Testing
- RRx-001
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- EpicentRx, Inc.
Advanced Solid Tumors, Malignant Neoplasm
A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002)
MK-2750 is a trial medicine designed to treat certain solid tumors. MK-2750 is a type of treatment called an antibody drug conjugate (ADC). ADCs attach to a protein on cancer cells and deliver medicine to destroy those cells.
- Trial name
- NCT07876128
- Testing
- MK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist
- Volunteers
- 300 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of NTKR-214 in combination with nivolumab in Japanese participants with advanced malignant tumors.
- Trial name
- NCT03745807
- Testing
- NKTR-214, Nivolumab
- Where
- Japan
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms, Malignant
Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
Primary Objectives: Study part 1: To determine the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicities (DLTs) of cabazitaxel administered as a 1-hour infusion in combination with gemcitabine, every 3 weeks in patients…
- Trial name
- NCT01001221
- Testing
- cabazitaxel, gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Sanofi